ESPR Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -1.75%, SMA50 -4.53%, SMA200 36.03%). The stock’s 14-day RSI is 47.3 (neutral), while the ATR of 0.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.52% below its high and over 385.2% above its low. Average 10-day trading volume of 36.05 million shares is significantly above the 3-month average of 12.54 million, indicating heightened recent market interest.

Esperion Therapeutics, Inc. generated EPS of -$0.54 over the past year. Five-year average earnings growth is 40.11%. The latest quarter delivered EPS of -$0.10. The next quarter is forecast at $0.27. Next year's EPS is expected at $98.27. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $3.16. The high target offers 403.14% upside. The low target suggests -0.63% downside. The mean target is $7.63. This offers 139.94% upside. Esperion Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 08, 2026, missed forecasts by 400.0%. The prior quarter beat by -75.0%. Over the last six quarters, Apple has recorded several small beats. These include 16.67% in May 06, 2025.

Esperion Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $1.10 and $4.18. With a market capitalization of about $661.15 million, Esperion Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.06). Key stats such as the average daily volume over the past year has been around 15.61 million shares, trading with heavier-than-usual volume. Headquartered in Ann Arbor, MI, Esperion Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sheldon L. Koenig, the company employs approximately 294 people and listed since June 26, 2013. Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol.

Esperion Therapeutics, Inc. has 201.62 million shares outstanding. The public float is 199.76 million shares, elevated short interest at 11.60% of float. This equals 23.13 million shares. The short ratio is 4.77 days. Institutional investors hold 50.9% of the float. Insiders own 0.56%. BIOTECH TARGET N V holds 4.48 million shares, Koenig Sheldon L. has 2.12 million shares and JANNEY DANIEL has 1.48 million shares. Over the past six months, insider transactions show net selling. They sold 115.58 thousand shares across 7 transactions.

Esperion Therapeutics, Inc. trades at a P/E ratio of -131.4, slightly below the S&P 500 average, with a price-to-sales ratio of 1.58 and a price-to-book ratio of -2.6 indicating negative book value, which may reflect financial stress. The P/FCF stands at -36.35, also below market averages.

Our AI price prediction model suggests that Esperion Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.63%, with price expected at $3.20 by July 24, 2026, within a range of $3.19 to $3.22 3-Month Outlook: Projected rise of 94.97%, reaching $6.20 by October 08, 2026, with a range of $6.01 to $6.41. 1-Year Outlook: Projected gain of 414.78%, with price at $16.37 by July 09, 2027, within a range of $13.02 to $23.02.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares are down -21.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Esperion Therapeutics, Inc. trading at a premium to the broader market with a P/E of -131.4. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $16.93, suggesting 432.39% upside. Our AI forecast model points to short-term strength (0.63% over two weeks), a medium-term rise (94.97% over three months), and a longer-term gain (414.78% over one year), with expected trading ranges indicating moderate volatility.